Skip to Main Content

Paper Details

The Prognostic Value of Posttreatment <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
J Nucl Med
10
2023
Author NameAffiliation
Anthony M JoshuaKinghorn Cancer Centre, St. Vincent's Hospital
Anthony M JoshuaGarvan Institute of Medical Research
Anthony M JoshuaSt. Vincent's Clinical School, University of New South Wales
Anthony M JoshuaUniversity of New South Wales
  • 1 - 4

Datasets

Release 1.2